Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | CYP51A1 | Q16850 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4452256 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2CYP19A1CFTRSLC6A2SLC6A4 | |
| SCHEMBL6280604 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2CYP19A1CFTRSLC6A2SLC6A4 | |
| SCHEMBL6344248 | 0.81 | CYP19A1 (0.50) | SMN1; SMN2CYP19A1CFTRSLC6A2SLC6A4 | |
| SCHEMBL128718 | 0.79 | CFTR (0.53) | SMN1; SMN2CYP19A1CFTRSLC6A2SLC6A4 | |
| SCHEMBL12303932 | 0.79 | CYP19A1 (0.47) | SMN1; SMN2CYP19A1CFTRSLC6A2SLC6A4 | |
| SCHEMBL25233552 | 0.77 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP19A1CFTRSLC6A2SLC6A4 | |
| SCHEMBL6075149 | 0.77 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP19A1CFTRSLC6A2SLC6A4 | |
| SCHEMBL1678107 | 0.77 | CYP3A4 (0.37) | SMN1; SMN2CYP19A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6074158 | 0.77 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP19A1CFTRSLC6A2SLC6A4 | |
| SCHEMBL6372735 | 0.77 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP19A1CFTRSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040181058-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2004-09-16 | — | — | US | claimed |
| CN-1497048-A | Method for preparing 3-heteroarylradical-3-hydroxy-propionic acid derivative | 拜尔公司 | 2004-05-19 | — | — | CN | claimed |
| CN-105367583-A | THIENO[2, 3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | UNIV LEUVEN KATH | 2016-03-02 | — | — | CN | disclosed |
| CN-102459280-B | Thieno [2,3-b ] pyridine derivatives as inhibitors of viral replication | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-10-14 | — | — | CN | disclosed |
| CN-100510093-C | Method for preparing 3-heteroarylradical-3-hydroxy-propionic acid derivative | SALTIGO GMBH (DE) | 2009-07-08 | — | — | CN | disclosed |
| US-7553970-B2 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2009-06-30 | — | — | US | disclosed |
| US-20060264641-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | BERENDES FRANK | 2006-11-23 | — | — | US | disclosed |
| US-20040181058-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2004-09-16 | — | — | US | disclosed |
| CN-1497048-A | Method for preparing 3-heteroarylradical-3-hydroxy-propionic acid derivative | 拜尔公司 | 2004-05-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181058-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | HPD, HAAO, GRHPR | SMN1; SMN2 4276/4885CYP19A1 359/4885CFTR 4515/4885 |
| US-20060264641-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | HPD, HAAO, GRHPR | SMN1; SMN2 4276/4885CYP19A1 359/4885CFTR 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.